Table A1.
Participant demographic and baseline clinical characteristics of the variant neutralization subset.
| Monovalent Omicron XBB.1.5-Adapted BNT162b2 30 μg |
Bivalent Omicron BA.4/BA.5-Adapted BNT162b2 a 30 μg |
|||||
|---|---|---|---|---|---|---|
| Characteristic | 18–55 y (N = 20) |
>55 y (N = 20) |
Total (N = 40) |
18–55 y (N = 20) |
>55 y (N = 20) |
Total (N = 40) |
| Sex, n (%) | ||||||
| Male | 12 (60.0) | 7 (35.0) | 19 (47.5) | 12 (60.0) | 7 (35.0) | 19 (47.5) |
| Female | 8 (40.0) | 13 (65.0) | 21 (52.5) | 8 (40.0) | 13 (65.0) | 21 (52.5) |
| Race, n (%) | ||||||
| White | 18 (90.0) | 16 (80.0) | 34 (85.0) | 17 (85.0) | 16 (80.0) | 33 (82.5) |
| Black | 2 (10.0) | 2 (10.0) | 4 (10.0) | 1 (5.0) | 3 (15.0) | 4 (10.0) |
| Other b | 0 | 2 (10) | 2 (5.0) | 2 (10) | 1 (5.0) | 3 (7.5) |
| Ethnicity, n (%) | ||||||
| Hispanic/Latino | 9 (45.0) | 4 (20.0) | 13 (32.5) | 3 (15.0) | 4 (20.0) | 7 (17.5) |
| Age at vaccination, years | ||||||
| Mean (standard deviation) | 38.0 (10.04) | 70.1 (6.51) | 54.0 (18.30) | 37.9 (9.97) | 69.7 (5.95) | 53.8 (18.00) |
| Median (range) | 35.5 (25–55) | 69.5 (56–82) | 55.5 (25–82) | 36.0 (25–54) | 69.5 (56–81) | 55.0 (25–81) |
| Baseline SARS-CoV-2 status, n (%) | ||||||
| Positive c | 20 (100.0) | 20 (100.0) | 40 (100.0) | 20 (100.0) | 20 (100.0) | 40 (100.0) |
| Time from last dose of mRNA COVID-19 vaccine to the study vaccination, months d | ||||||
| Mean (SD) | 8.8 (1.98) | 9.4 (2.53) | 9.1 (2.26) | 11.0 (1.41) | 11.4 (1.16) | 11.2 (1.29) |
| Median (range) | 8.3 (5.8–12.0) | 10.2 (2.0–11.9) | 9.5 (2.0–12.0) | 11.3 (7.4–12.8) | 11.9 (8.5–12.6) | 11.4 (7.4–12.8) |
| Body mass index, n (%) | ||||||
| Underweight (<18.5 kg/m2) | 0 | 1 (5.0) | 1 (2.5) | 0 | 0 | 0 |
| Normal weight (≥18.5–24.9 kg/m2) | 6 (30.0) | 6 (30.0) | 12 (30.0) | 5 (25.0) | 3 (15.0) | 8 (20.0) |
| Overweight (≥25.0–29.9 kg/m2) | 9 (45.0) | 7 (35.0) | 16 (40.0) | 8 (40.0) | 12 (60.0) | 20 (50.0) |
| Obese (≥30.0 kg/m2) | 5 (25.0) | 6 (30.0) | 11 (27.5) | 7 (35.0) | 5 (25.0) | 12 (30.0) |
a Comparator group from another study (ClinicalTrials.gov Identifier: NCT05472038). b Includes American Indian or Alaska native, Asian, and multiracial. c Positive SARS-CoV-2 nucleoprotein–binding antibody result at baseline, positive nucleic acid amplification test result at baseline, or medical history of COVID-19. d Month was calculated as 28 days.